Global market for peripheral drug eluting balloons (DEBs) is poised for significant
expansion, with projections indicating a robust growth trajectory over the forecast
period from 2024 to 2031. According to latest market analysis, the peripheral DEB
market size is expected to surge to US$1800 million by 2031, marking a substantial
increase from the US$950 million recorded in 2024. This growth is anticipated to be
driven by several key factors, including technological advancements, rising
prevalence of Peripheral Artery Disease (PAD), and a growing preference for
minimally invasive procedures.
For More Industry Insights Read:
https://www.fairfieldmarketresearch.com/report/peripheral-drug-eluting-balloonsmarket
Steady Growth Trajectory and Key Market Dynamics
The Global peripheral DEB market has witnessed consistent growth owing to
advancements in cardiovascular treatment, increased prevalence of PAD, and a shift
towards minimally invasive procedures. Between 2019 and 2023, the market
demonstrated a positive trajectory with a projected Compound Annual Growth Rate
(CAGR) of 9.56%. This growth is attributed to the efficacy of DEBs in reducing
restenosis rates and the escalating demand for minimally invasive treatment options.
Factors contributing to the continued growth of the market from 2024 to 2031 include
ongoing advancements in cardiovascular treatment, a rising prevalence of PAD, and
a preference for minimally invasive procedures among both patients and healthcare
providers. However, significant barriers such as regulatory hurdles, limited clinical
evidence, and cost constraints continue to influence adoption rates and
reimbursement policies, shaping the market landscape.
Key Trends and Opportunities
Several key trends and opportunities are shaping the peripheral DEB market. These
include:
Digital Health Integration: The integration of digital health features into medical
devices is gaining momentum, offering benefits such as remote monitoring and
personalized treatment options. Peripheral DEBs with digital monitoring capabilities
could provide real-time data on drug release and patient response, thereby
enhancing treatment strategies.
Focus on Minimally Invasive Procedures: The shift towards minimally invasive
procedures across various medical specialties, including cardiovascular
interventions, is expected to drive the demand for innovative devices like peripheral
DEBs. Patients favor minimally invasive techniques due to shorter recovery times
and reduced risk of complications, leading to increased adoption of DEBs.
Expansion into Emerging Markets: Emerging markets present significant
opportunities for peripheral DEB manufacturers to address unmet medical needs and
drive revenue growth. Developing countries are witnessing a rise in the prevalence
of cardiovascular diseases, creating demand for advanced medical treatments.
Regional Frontrunners
1. North America: North America leads in innovations and market dominance,
supported by factors such as high healthcare expenditure and advanced
healthcare infrastructure. However, market saturation and stringent regulatory
requirements pose challenges for new entrants.
2. Europe: Europe experiences robust growth in the peripheral DEB market,
driven by the increasing incidence of PAD and a growing preference for
minimally invasive procedures. Pricing pressures and regulatory complexities
could impede market growth to some extent.
3. Asia Pacific: The Asia Pacific region emerges as a high-potential market for
peripheral DEBs, fueled by factors such as the rising geriatric population and
improving healthcare infrastructure. However, challenges such as fragmented
healthcare systems and reimbursement issues hinder market growth in
certain countries.
Competitive Landscape
The competitive landscape of the peripheral DEB market is characterized by intense
rivalry among key players striving for market dominance. Leading companies such
as Medtronic plc, Boston Scientific Corporation, Cook Medical, Inc., and Becton,
Dickinson and Company are prominent players in this segment. These companies
adopt various growth strategies including product innovation, strategic partnerships,
mergers and acquisitions, and geographical expansion to maintain their competitive
edge.
Leaders in the Peripheral Drug Eluting Balloons Market Space
1. Abbott Laboratories
2. Boston Scientific Corporation
3. Cook Medical Inc.
4. MicroPort Scientific Corporation (Endovastec™)
5. Medtronic Plc.
6. Cardinal Health, Inc.
7. B. Braun Melsungen AG
8. BIOTRONIK SE & Co. KG
9. Becton, Dickinson and Company
10. W. L. Gore & Associates Inc.
11. Getinge AB
12. Terumo Corp
13. Kyoto Medical Planning Co Ltd
14. iVascular S.L.U
15. AMG International GmbH
16. ENDOCOR GmbH
17. Meril Life Sciences Pvt. Ltd.
18. Nano Therapeutics Pvt Ltd
19. Koninklijke Philips N.V.
20. REVA Medical